Abstract:BACKGROUND Gastric cancer (GC) is one of the most common and deadliest types of cancer worldwide due to its delayed diagnosis and high metastatic frequency, but its exact pathogenesis has not been fully elucidated. ETS homologous factor (EHF) is an important member of the ETS family and contributes to the pathogenesis of multiple malignant tumors. To date, whether EHF participates in the development of GC via the c-Met signaling pathway remains unclear. AIM To investigate the role and mechanism of EHF in the occurrence and development of GC. METHODS The expression of EHF mRNA in GC tissues and cell lines was measured by quantitative PCR. Western blotting was performed to determine the protein expression of EHF, c-Met, and its downstream signal molecules. The EHF expression in GC tissues was further detected by immunohistochemical staining. To investigate the role of EHF in GC oncogenesis, small interfering RNA (siRNA) against EHF was transfected into GC cells. The cell proliferation of GC cells was determined by Cell Counting Kit-8 and colony formation assays. Flow cytometry was performed following Annexin V/propidium iodide (PI) to identify apoptotic cells and PI staining to analyze the cell cycle. Cell migration and invasion were assessed by transwell assays. RESULTS The data showed that EHF was upregulated in GC tissues and cell lines in which increased expression of c-Met was also observed. Silencing of EHF by siRNA reduced the proliferation of GC cells. Inhibition of EHF induced significant apoptosis and cell cycle arrest in GC cells. Cell migration and invasion were significantly inhibited. EHF silencing led to c-Met downregulation and further blocked the Ras/c-Raf/extracellular signal-related kinase 1/2 (Erk1/2) pathway. Additionally, phosphatase and tensin homolog was upregulated and glycogen synthase kinase 3 beta was deactivated. Moreover, inactivation of signal transducer and activator of transcription 3 was detected following EHF inhibition, leading to inhibition of the epithelial-to-mesenchymal transition (EMT). CONCLUSION These results suggest that EHF plays a key role in cell proliferation, invasion, apoptosis, the cell cycle and EMT via the c-Met pathway. Therefore, EHF may serve as an antineoplastic target for the diagnosis and treatment of GC.

HGF/c-Met Axis: the Advanced Development in Digestive System Cancer

MicroRNAs and Long Non-coding RNAs in c-Met-Regulated Cancers

Cmet As A Potential Therapeutic Target In Gastric Cancer

Research progress on the development of hepatocyte growth factor/c-Met signaling pathway in gastric cancer: A review

Progress and Challenge in Development of Biotherapeutics Targeting MET Receptor for Treatment of Advanced Cancer.

Potential Therapeutics Specific to C-Met/ron Receptor Tyrosine Kinases for Molecular Targeting in Cancer Therapy.

Blockage of ETS Homologous Factor Inhibits the Proliferation and Invasion of Gastric Cancer Cells Through the C-Met Pathway

Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities

HGF/c-Met pathway inhibition combined with chemotherapy increases cytotoxic T-cell infiltration and inhibits pancreatic tumour growth and metastasis

Targeting HGF/c-MET Axis in Pancreatic Cancer

Role of HGF/c-Met Signaling in Tumorigenesis and the Tumor Therapy Therewith

Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement

Role of HGF/c‐Met in the treatment of colorectal cancer with liver metastasis

Unveiling the Role of HGF/c-Met Signaling in Non-Small Cell Lung Cancer Tumor Microenvironment

AXL and MET in Hepatocellular Carcinoma: A Systematic Literature Review

Molecular mechanism study of HGF/c-MET pathway activation and immune regulation for a tumor diagnosis model

Synergistic Antitumor Effects of Cmet Inhibitor in Combination with Anti-Vegf in Colorectal Cancer Patient-Derived Xenograft Models

Targeting the hedgehog pathway in MET mutation cancers and its effects on cells associated with cancer development

Recent Advances in the Design and Synthesis of c-Met Inhibitors as Anticancer Agents (2014-Present)

Establishment of Patient-Derived Gastric Cancer Xenografts: a Useful Tool for Preclinical Evaluation of Targeted Therapies Involving Alterations in HER-2, MET and FGFR2 Signaling Pathways

Advances in the diagnosis and treatment of MET-variant digestive tract tumors